Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Look for Journavx to become a massive blockbuster drug for Vertex. It won U.S. Food and Drug Administration (FDA) approval earlier this year for treating acute pain. The big plus for Journavx is that ...

proudly congratulates and announces its role in supporting Vertex Pharmaceuticals' clinical studies that led to the FDA approval of JOURNAVX™ (suzetrigine), the first-in-class, non-opioid oral ...

The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to ...

Corrigan-Curay emphasized that Journavx could “mitigate certain risks associated with using an opioid for pain.” The FDA’s official account on X also tweeted the news — the agency’s ...